SPECTRUM PHARMACEUTICALS INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2023-08-01: Form 8-K; Period of report 2023-07-31; Description 2.01 Completion of Acquisition or Disposition of Assets; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 3.03 Material Modification to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events; Details 2.01.
- 2023-07-27: Form 8-K; Period of report 2023-07-27; Description 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events; Details 5.07.
- 2023-05-17: Form 8-K; Period of report 2023-05-16; Description 8.01 Other Events; Details 8.01.
- 2023-05-09: Form 8-K; Period of report 2023-05-09; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2023-08-01 | 8-K | 2023-07-31 | 2.01 Completion of Acquisition or Disposition of Assets; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 3.03 Material Modification to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events | 2.01 The information set forth in the Introductory Note and under Items 3.01, 3.03, 5.01, 5.02, 5.03 and 8.01 of this Current Report on Form 8-K is incorporated by reference in its entirety into this Item 2.01. 3.01 In connection with the consummation of the Merger, the Company notified representatives of the Nasdaq Capital Market (“NASDAQ”) that the Merger had been completed and requested that NASDAQ delist the Common Stock. 3.03 The information set forth in the Introductory Note and Items 2.01, 3.01, 5.01, 5.02 and 5.03 of this Current Report on Form 8-K is incorporated herein by reference in its entirety into this Item 3.03. 5.01 The information set forth in the Introductory Note and under Items 2.01 and 5.02 of this Current Report on Form 8-K is incorporated by reference in its entirety into this Item 5.01. 5.02 The information set forth in the Introductory Note and under Item 2.01 of this Current Report on Form 8-K is incorporated by reference in its entirety into this Item 5.02. 5.03 The information set forth in the Introductory Note and under Item 2.01 of this Current Report on Form 8-K is incorporated by reference in its entirety into this Item 5.03. 8.01 On July 31, 2023, Assertio issued a press release announcing the completion of the Merger, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. | d332583d8k.htm |
| 2023-07-27 | 8-K | 2023-07-27 | 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events | 5.07 On July 27, 2023, Spectrum Pharmaceuticals, Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”) in connection with the proposed merger (the “Merger”) of Spade Merger Sub 1, Inc., a Delaware corporation (“Merger Sub”) and a wholly-owned subsidiary of Assertio Holdings, Inc., a Delaware corporation (“Acquiror”), with and into the Company, with the Company continuing as the surviving corporation in the Merger and becoming a wholly-owned subsidiary of Acquiror. 8.01 On July 27, 2023, the Company and Acquiror issued a joint press release announcing the voting results of the Special Meeting and the special meeting of Acquiror stockholders. | d519473d8k.htm |
| 2023-05-17 | 8-K | 2023-05-16 | 8.01 Other Events | 8.01 On May 16, 2023, Spectrum Pharmaceuticals, Inc. (the “Company”) received written notice (the “Notification Letter”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company had regained compliance with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market because the Company’s common stock had a closing bid price of at least $1.00 per share for ten consecutive business days. | d449587d8k.htm |
| 2023-05-09 | 8-K | 2023-05-09 | 2.02 Results of Operations and Financial Condition | 2.02 On May 9, 2023, Spectrum Pharmaceuticals, Inc. issued a press release, which, among other matters, sets forth our results of operations for the quarter ended March 31, 2023. | d261215d8k.htm |
| 2023-05-01 | 8-K | 2023-04-25 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 25, 2023, Spectrum Pharmaceuticals, Inc. (the “Company”) entered into the Executive Employment Agreement (the “Amended Employment Agreement”) with Keith M. McGahan, its Chief Legal Officer. | d477272d8k.htm |
| 2023-04-25 | 8-K | 2023-04-24 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On April 25, 2023, the Company and Assertio issued a joint press release announcing they had entered into the Merger Agreement. | tm2313713d1_8k.htm |
| 2023-04-04 | 8-K | 2023-03-30 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 On March 30, 2023, the Board of Directors of Spectrum Pharmaceuticals, Inc. (the “Company”) approved and adopted the Fourth Amended and Restated Bylaws of the Company (the “Restated Bylaws”), which became effective immediately. | d471040d8k.htm |
| 2023-04-03 | 8-K | 2023-04-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 1, 2023, Spectrum Pharmaceuticals, Inc. (the “Company”) entered into a new employment agreement (the “Employment Agreement”) with Thomas J. Riga, President and Chief Executive Officer of the Company, effective as of April 11, 2023. | d486703d8k.htm |
| 2023-03-22 | 8-K | 2023-03-22 | 2.02 Results of Operations and Financial Condition | 2.02 On March 22, 2023, Spectrum Pharmaceuticals, Inc. issued a press release, which, among other matters, sets forth our results of operations for the quarter ended December 31, 2022. | sppi-20230322.htm |
| 2023-03-10 | 8-K | 2023-03-10 | 7.01 Regulation FD Disclosure | 7.01 Spectrum Pharmaceuticals, Inc. informs its investors that it does not hold cash deposits or securities at Silicon Valley Bank. | d460118d8k.htm |
| 2023-02-09 | 8-K | 2023-02-08 | 8.01 Other Events | 8.01 On February 8, 2023, Spectrum Pharmaceuticals, Inc. issued a press release announcing that a permanent J-code, J1449, has been issued for ROLVEDON (eflapegrastim-xnst) Injection by the U.S. Centers for Medicare & Medicaid Services effective as of April 1, 2023. | d447282d8k.htm |
| 2023-01-31 | 8-K | 2023-01-31 | 2.02 Results of Operations and Financial Condition | 2.02 On January 31, 2023, Spectrum Pharmaceuticals, Inc. issued a press release, which, among other matters, sets forth certain estimated preliminary unaudited financial results for the quarter and year ended December 31, 2022. | d745957d8k.htm |
| 2023-01-04 | 8-K | 2022-12-31 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 4, 2023, Spectrum Pharmaceuticals, Inc. (the “Company”) reported that Dr. Francois Lebel resigned from employment as the Company’s Executive Vice President and Chief Medical Officer, effective December 31, 2022 (the “Termination Date”). | d437750d8k.htm |